K 001

Drug Profile

K 001

Alternative Names: K-001; Peptidoglycan complex of spirulina

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hwealth Pharmaceutical; Shanghai Jiaotong University School of Medicine
  • Developer Shanghai Jiaotong University School of Medicine
  • Class Amino acids; Antineoplastics; Polysaccharides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer

Most Recent Events

  • 22 Nov 2017 K 001 has patent protection in China, Japan and USA
  • 17 Nov 2017 Hwealth Pharmaceutical and Shanghai Jiaotong University School of Medicine plans a phase II/III trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (ChiCTR-IIR-17013424)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top